Please login to the form below

RNA interference

This page shows the latest RNA interference news and features for those working in and with pharma, biotech and healthcare.

Novo Nordisk hits pause on rival to Hemlibra for haemophilia

Meanwhile, another non-clotting factor drug for haemophilia – Alnylam and Sanofi’s RNA interference candidate fitusiran – is also in late-stage development for haemophilia A and B.

Latest news

China backs use of Roche’s Actemra for coronavirus

Alnylam meanwhile says it is working with Vir Biotech on RNA interference drugs targeting ‘highly-conserved regions’ of COVID-19 RNA.
Alnylam’s third RNAi drug clears phase 3 trial in rare kidney disease

RNA interference (RNAi) drug lumasiran works upstream of the deficient enzyme, switching off production of a substrate that it converts to oxalate.
FDA clears Alnylam’s second RNAi drug for rare disease

Alnylam has claimed a second US approval for one of its RNA interference (RNAi) drugs, getting an FDA nod for acute hepatic porphyria drug Givlaari.
Eli Lilly shutters UK neuroscience unit, with 80 job losses expected

It also said shifting the neuroscience projects to the US will make it easier for Lilly apply new technologies like RNA interference and gene therapy to the neuroscience projects.
Arbutus hit hard as new hep B drug fails on safety

Last December, the company reported disappointing results in a phase 2 trial of a RNA interference candidate called ARB-1467, handing a competitive advantage to Arrowhead Pharmaceuticals whose rival drug ... It has since abandoned the programme in favour

More from news
Approximately 1 fully matching, plus 42 partially matching documents found.

Latest Intelligence

20 for 2020 – Five pharma leaders to watch in 2020

More than a decade of research into its RNA interference (RNAi) drugs generated the first ever approval of a drug in this category towards the end of 2018, and the company

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

Silence appoints chief medical officer

These studies involve Silence's investigational portfolio of RNA interference (RNAi) therapeutics, which aim to treat conditions by selectively turning off genes expressed in an individual with a certain disease.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...: Highly Competitive Day Rate, Bonus &Benefits

Senior Account Director & Associate Director - Healthcare Ad...: Highly Competitive Salary, Bonus &Benefits

Senior Leadership Role – Medical Communications – North West: Highly Competitive Salary, Bonus &Benefits

Client Services Director – London or Home Based – Medical Commun...: Highly Competitive Salary, Bonus &Benefits

Freelance Medical Writer - Creative Healthcare Comms - 2 month t...: Excellent Day Rate

Editor & Senior Editor - Medical Communications - Home Based: Highly Competitive Salary, Bonus &Benefits

Medical Writer, Senior Medical Writer, Principal Medical Writer,...: Highly Competitive Salary, Bonus &Benefits

Home Working Medical Copy Writer & Senior Medical Copy Write...: Highly Competitive Salary, Bonus &Benefits

Senior Content Editor - Biotechnology: Salary TBC

Senior Account / Programme Manager - MedComms - Buckinghamshire: Highly Competitive Remuneration packages

Freelance Account Manager - Creative Healthcare Comms - Immediat...: Excellent Day Rate

Account Management: Competitive Salary Offered

PMHub

Add my company

Impetus Digital

Impetus Digital has offered virtual advisory boards, clinical trial investigator consortiums, co-author publication working groups, steering committees, and medical education...

Latest intelligence

InSite Events™ National Pharma Meeting: A Customer Story: How our client leveraged Impetus Digital’s white-glove service, 360° coverage and care, and award-winning InSite Events™ platform to successfully transfer their annual national meeting online....
Fear or encouragement, which is best to drive behaviour change?: The communications industry depends on fear of the perceived loss of something, in order to create the hope found in a product benefit. But, if if left too long unchecked,...
The unheard, unseen, and uncorrected effects of COVID-19: The disproportionate effects of the pandemic have been highlighted amongst ethnic minorities, so is it likely that ethnic minorities will be more worried about participating? And could this exacerbate inequalities...